top of page
錨點 1

Amyloid

Progress_of_Brain_Amyloid_Deposition_in_

Oct. 2018

Progress of Brain Amyloid Deposition in Familial Alzheimer’s Disease with Taiwan D678H APP Mutation

Weng YC, Hsiao IT†, Huang CY, Huang KL, Liu CH, Chang TY, Yen TC, Lin KJ, Huang CC.  

J Alzheimers Dis. 2018 Oct 66(2):775-787.

The amyloid AV-45 (florbetapir) positron emission tomography (PET) has been used in the study of the familial Alzheimer’s disease (FAD) with the D678H amyloid precursor protein (APP) mutation. In addition, the progress of the disease remains unknown.

We aim to investigate the progression rate of amyloid accumulation in FAD patients with this mutation by neuroimages analysis.

Diversity of neurodegenerative pathophys

Jun. 2018

Diversity of neurodegenerative pathophysiology in nondemented patients with major depressive disorder: Evidence of cerebral amyloidosis and hippocampal atrophy

Wu KY, Lin KJ, Chen CH, Chen CS, Liu CY, Huang SY, Yen TC, Hsiao IT.

Brain Behav. 2018 Jul;8(7):e01016. 

Patients with late‐life depression may be at the preclinical stage of dementia. However, the neurodegenerative processes in late‐life depression are poorly understood. This study aimed to investigate the distribution patterns of amyloid pathology and neurodegeneration in a depressive population without dementia.

Correlation of early-phase F-18 Florbeta

Jan. 2012

Correlation of early-phase F-18 Florbetapir (AV-45/Amyvid) PET images to FDG images: Preliminary studies. 

IT Hsiao, CC Huang, CJ Hsieh, WC Hsu, SP Wey, TC Yen, MP Kung, KJ Lin, 

European Journal of Nuclear Medicine and Molecular Imaging. Apr 2012. 39(4):613-20.

18F-Florbetapir (AV-45/Amyvid) is a novel posi-tron emission tomography (PET) tracer for imaging plaquepathology in Alzheimer’s disease (AD), while PET imagesof fluorodeoxyglucose (FDG) for cerebral glucose metabo-lism can provide complementary information to amyloidplaque images for diagnosis of AD. The goal of this prelim-inary study was to investigate the perfusion-like property ofrelative cerebral blood flow estimates (R1) and summedearly-phase AV-45 images [perfusion AV-45 (pAV-45)] andoptimize the early time frame for pAV-45.

  1. KY Wu, KJ Lin, CH Chen, CY Liu, YM Wu, CS Chen, TC Yen, IT Hsiao. (2022). Decreased Cerebral Amyloid-β Depositions in Patients With a Lifetime History of Major Depression With Suspected Non-Alzheimer Pathophysiology. Frontiers in Aging Neuroscience. 14. 857940. 10.3389/fnagi.2022.857940. 

  2. SY Huang, JL Hsu, KJ Lin and IT Hsiao* , Alzheimer’s Disease Neuroimaging Initiative†.  A Novel Individual Metabolic Brain Network for 18F-FDG PET Imaging.  Front. Neurosci., 2020 May; 14: 344.

  3. CC Weng, IT Hsiao+, QF Yang, CH Yao , CY Tai, MF Wu, TC Yen, MK Jang, KJ Lin. Characterization of 18 F-PM-PBB3 ( 18 F-APN-1607) Uptake in the rTg4510 Mouse Model of Tauopathy. Molecules. 2020 Apr 10;25(7):1750. doi: 10.3390/molecules25071750.

  4. Hsu JL, Lin KJ, Hsiao IT, Huang KL, Liu CH, Wu HC, Weng YC, Huang CY , Chang CC, Yen TC, Higuchi M, Jang MK, Huang CC. The imaging features and clinical associations of a novel tau PET tracer - 18F-APN1607(18F-PM-PBB3) in Alzheimer’s disease. Cognitive Neuroscience. 2020 Oct;45(10):747-756.

  5. Wei YC, Tseng JR, Wu CL, Su FC, Weng WC, Hsu CC, Chang KH, Wu CF, Hsiao IT, Lin CP. Different FDG-PET metabolic patterns of anti-AMPAR and anti-NMDAR encephalitis: Case report and literature review. Brain Behav. 2020 Mar;10(3):e01540.

  6. Lin SY, Lin KJ, Lin PC, Huang CC, Chang CC, Lee YC, Hsiao IT, Yen TC, Huang WS, Yang BH, Wang PN. Plasma amyloid assay as a pre-screening tool for amyloid positron emission tomography imaging in early stage Alzheimer’s disease. Alzheimers Res Ther. 2019 Dec 27;11(1):111.

  7. Cheng CH, Lin KJ, Hong CT, Wu D, Chang HM, Liu CH, Hsiao IT, Yang CP, Liu YC, Hu CJ. Plasmon-Activated Water Reduces Amyloid Burden and Improves Memory in Animals with Alzheimer’s Disease. Sci Rep. 2019 Sep 13;9(1):13252.

  8. Huang CY, Hsiao IT†, Lin KJ, Huang KL, Fung HC, Liu CH, Chang TY, Weng YC, Hsu WC, Yen TC, Huang CC. Amyloid PET pattern with dementia and amyloid angiopathy in Taiwan familial AD with D678H APP mutation. Neurological Sciences. 2019 Jan 398:107-116.

  9. Weng YC, Hsiao IT†, Huang CY, Huang KL, Liu CH, Chang TY, Yen TC, Lin KJ, Huang CC. Progress of Brain Amyloid Deposition in Familial Alzheimer’s Disease with Taiwan D678H APP Mutation. J Alzheimers Dis. 2018 Oct 66(2):775-787.

  10. Wu KY, Lin KJ, Chen CH, Chen CS, Liu CY, Huang SY, Yen TC, Hsiao IT. Diversity of neurodegenerative pathophysiology in nondemented patients with major depressive disorder: Evidence of cerebral amyloidosis and hippocampal atrophy. Brain Behav. 2018 Jul;8(7):e01016. doi: 10.1002/brb3.1016. Epub 2018 Jun 21.

  11. Wu KY, Hsiao IT†, Chen CH, Liu CY, Hsu JL, Huang SY, Yen TC, Lin KJ.  Plasma Aβ analysis using magnetically-labeled immunoassays and PET 18F-florbetapir binding in non-demented patients with major depressive disorder.  Sci Rep. 2018 Feb 9;8(1):2739.

  12. Lee TH, Huang KL, Chang TY, Ho MY, Wey SP, Hsieh CJ, Yen TC, Lin KJ*, Hsiao IT*. Early-phase 18F-AV-45 PET Imaging can Detect Crossed Cerebellar Diaschisis Following Carotid Artery Stenosis and Cerebral Hypoperfusion. Curr Neurovasc Res. 2017 Jun 21;14(3):258-265.

  13. Kuo HC, Hsiao IT†, Hsieh CJ, Huang CY, Huang KL, Wai YY, Chuang WL, Kung MP, Chu YC, Yen TC, Lin KJ, Huang CC. Dual-phase 18F-florbetapir positron emission tomography in patients with primary progressive aphasia, Alzheimer's disease, and healthy controls: A preliminary study. J Formos Med Assoc. 2017 Dec;116(12):964-972.

  14. Li P, Hsiao IT†(Contributed equally), Liu CY, Chen CH, Huang SY, Yen TC, Wu KY, Lin KJ. Beta-amyloid deposition in patients with major depressive disorder with differing levels of treatment resistance: a pilot study. EJNMMI Res. 2017 Mar.;7(1):24.

  15. Lin KJ, Hsiao IT, Hsu JL, Huang CC, Huang KL, Hsieh CJ, Wey SP, Yen TC, Imaging characteristic of dual-phase (18)F-florbetapir (AV-45/Amyvid) PET for the concomitant detection of perfusion deficits and beta-amyloid deposition in Alzheimer's disease and mild cognitive impairment. European Journal of Nuclear Medicine and Molecular Imaging. 2016 Jul. 43(7):1304-14.

  16. KY Wu, CY Liu, CS Chen, CH Chen, IT Hsiao, CJ Hsieh, CP Lee, TC Yen, KJ Lin. Beta-amyloid deposition and cognitive function in patients with major depressive disorder with different subtypes of mild cognitive impairment: F18-florbetapir (AV-45/Amyvid) PET study. European Journal of Nuclear Medicine and Molecular Imaging. 2016 Jun. 43(6):1067-76.

  17. ST Yang, IT Hsiao, CJ Hsieh, YH Chiang, TC Yen, WT Chiu , KJ Lin, CJ Hu, Accumulation of amyloid in cognitive impairment after mild traumatic brain injury. Journal of the Neurological Sciences. 2015 Feb 15 ;349(1-2):99-104.

  18. KY Wu#, IT Hsiao#, CS Chen, CH Chen, CJ Hsieh, YY Wai, CJ Chang, HJ Tseng, CY Liu, KJ Lin, Increased brain amyloid deposition in patients with a lifetime history of major depression: Evidenced on 18F-Florbetapir (AV-45/Amyvid) positron emission tomography.  European Journal of Nuclear Medicine and Molecular Imaging. (Equal Contribution) Apr 2014. 41(4): 714-722.

  19. IT Hsiao, CC Huang, CJ Hsieh, SP Wey, MP Kung, TC Yen, KJ Lin, Perfusion-like template and standardized normalization-based brain image analysis using 18F-florbetapir (AV-45/Amyvid) PET, European Journal of Nuclear Medicine and Molecular Imaging. Jun 2013. 40(6):908-920.

  20. KL Huang, KJ Lin, IT Hsiao, HC Kuo, WC Hsu, WL Chuang, MP Kung, SP Wey, CJ Hsieh, YY Wai, TC Yen*, CC Huang*, Regional amyloid deposition in amnestic mild cognitive impairment and Alzheimer's disease evaluated by [18F]AV-45 positron emission tomography in Chinese population. PLOS ONE. Mar 2013. 8(3):e58974. 

  21. KL Huang, KJ Lin, MY Ho, YJ Chang, CH Chang, SP Wey, CJ Hsieh, TC Yen, IT Hsiao*, and TH Lee*, Amyloid deposition after cerebral hypoperfusion: Evidenced on [18F]AV-45 positron emission tomography. Journal of the Neurological Sciences. Aug 2012. 15;319(1-2):124-9. 

  22. MP Kung, CC Weng, KJ Lin, IT Hsiao, TC Yen and SP Wey, Amyloid Plaque Imaging from IMPY/SPECT to AV-45/PET. Chang Gung Medical Journal. Jun 2012.35(3):211-8

  23. IT Hsiao, CC Huang, CJ Hsieh, WC Hsu, SP Wey, TC Yen, MP Kung, KJ Lin, Correlation of early-phase F-18 Florbetapir (AV-45/Amyvid) PET images to FDG images: Preliminary studies. European Journal of Nuclear Medicine and Molecular Imaging. Apr 2012. 39(4):613-20.

  24. CH Yao, KJ Lin, CC Weng, IT Hsiao, YS Ting, TC Yen, TR Jan, Daniel Skovronsky, MP Kung and SP Wey, “GMP-compliant automated synthesis of [18F]AV-45 (Florbetapir F 18) for imaging β-amyloid plaques in human brain”, Applied Radiation and Isotopes. Dec 2010. 68(12):2293-2297. 

  25. KJ Lin, WC Hsu, IT Hsiao, SP Wey, LW Jin, D Skovronsky, YY Wai, HP Chang, CW Lo, CH Yao, TC Yen, MP Kung. “Whole-Body Biodistribution and Brain PET Imaging with 18F-AV-45, a Novel Amyloid Imaging Agent-a Pilot Study.” Nuclear Medicine and Biology. May 2010. 37(4):497-508.

bottom of page